Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Product sales	$ 2,557,765	$ 1,989,988	$ 4,923,966	$ 3,842,005
Cost of product sales	956,839	872,835	1,885,241	1,643,840
Gross profit	1,600,926	1,117,153	3,038,725	2,198,165
Operating expenses
Research and development	318,607	599,031	605,358	1,103,270
Sales and marketing	546,455	849,193	1,058,399	1,583,106
General and administrative	1,077,067	1,262,818	2,180,210	2,598,110
Total operating expenses	1,942,129	2,711,042	3,843,967	5,284,486
Operating loss	(341,203)	(1,593,889)	(805,242)	(3,086,321)
Other income (expenses), net
Interest income	76	445	124	2,364
Interest expense, related party	(104,582)	(8,333)	(187,915)	(8,333)
Amortization of debt discount	(62,398)	(31,199)	(155,996)	(31,199)
Write-off of deferred financing costs	0	(86,736)	0	(86,736)
Loss from equity-method investment in SAVSU	(260,105)	0	(489,473)	0
Total other income (expenses), net	(427,009)	(125,823)	(833,260)	(123,904)
Net loss	(768,212)	(1,719,712)	(1,638,502)	(3,210,225)
Net loss attributable to non-controlling interest	0	363,629	0	627,314
Net loss attributable to BioLife Solutions, Inc.	$ (768,212)	$ (1,356,083)	$ (1,638,502)	$ (2,582,911)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.06)	$ (0.11)	$ (0.13)	$ (0.21)
Basic and diluted weighted average common shares used to calculate net loss per common share (in shares)	13,100,820	12,568,041	13,033,106	12,512,949